

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 56040

**Title:** PSGL-1 deficiency prevents the development of acute pancreatitis by attenuating the leukocytes infiltration

**Reviewer's code:** 03310785

**Position:** Peer Reviewer

**Academic degree:** MD, PhD

**Professional title:** Professor

**Reviewer's Country/Territory:** Japan

**Author's Country/Territory:** China

**Manuscript submission date:** 2020-04-14

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2020-04-15 10:12

**Reviewer performed review:** 2020-04-17 09:22

**Review time:** 1 Day and 23 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input checked="" type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

## **SPECIFIC COMMENTS TO AUTHORS**

Although the findings that PSGL-1 deficiency prevents the development of acute pancreatitis by attenuating leukocyte infiltration are interesting, a number of points need clarifying and certain statements require further justification. These are given below.

<Points> 1. Details of PSGL-1<sup>-/-</sup> mice should be described. The authors only described that "PSGL-1<sup>+/+</sup> and PSGL-1<sup>-/-</sup> mice were obtained from Department of Molecular Biology and Biochemistry, University of Oklahoma Health Science Center". Most of readers cannot understand how the knockout mice were established. Whether the mice were established by Yang, J. et al. (J. Exp. Med. 190, 1769-1782, 1999) should be clarified. 2. The authors described, "All patients and volunteers signed the informed consent form, which was approved by hospital's ethics committee (QT19012)". Please provide the approval number and approval date. 3. The authors described, "All experimental protocols were approved by the Animal Care and Use Committee at the Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Peking Union Medical College (YZW19007)". Please provide the approval number and approval date. 4. The authors described, "The inflammatory cytokines IL-1 $\beta$  and IL-6 in the serum or supernatant were tested by ELISA kits". What ELISA kit(s) were used should be described. 5. The authors described, "TUNEL assay was performed according to the instructions of the TUNEL kit" without describing what kit was used. What kit was used should be described. 6. In Materials and Methods, "providers (city, country [State])" should be clearly described. For example, "Sigma (USA)" should be changed to "Sigma (St. Louis, MO)"; "Selleck" should be changed to "Selleck (Huston, TX)". 7. The manuscript contains multiple errors in English writing; therefore, it should be checked by native English speakers/scientists before submission.